Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | DHODH | Q02127 | 5/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3908785 | 0.82 | OPRM1 (0.45) | — | |
| SCHEMBL2725472 | 0.81 | NAAA (0.38) | DHODH | |
| SCHEMBL28009777 | 0.81 | DHODH (0.35) | DHODH | |
| SCHEMBL28009779 | 0.81 | DHODH (0.35) | DHODH | |
| SCHEMBL3900984 | 0.81 | OPRM1 (0.46) | DHODH | |
| SCHEMBL2726471 | 0.79 | DHODH (0.33) | DHODH | |
| SCHEMBL2728334 | 0.78 | DHODH (0.36) | DHODH | |
| SCHEMBL2725884 | 0.78 | DHODH (0.36) | DHODH | |
| SCHEMBL2728330 | 0.78 | DHODH (0.36) | DHODH | |
| SCHEMBL2725229 | 0.78 | DHODH (0.36) | DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9737504-B2 | Dihydroorotic and acid dehydrogenase inhibitor | INSTITUTE OF MITOCHONDRIA SCIENCE, INC. (JP) | 2017-08-22 | — | — | US | disclosed |
| US-9737504-B2 | Dihydroorotic and acid dehydrogenase inhibitor | INSTITUTE OF MITOCHONDRIA SCIENCE, INC. (JP) | 2017-08-22 | — | — | US | disclosed |
| US-20160296494-A1 | DIHYDROOROTIC AND ACID DEHYDROGENASE INHIBITOR | NAI INC. | 2016-10-13 | — | — | US | disclosed |
| US-20160296494-A1 | DIHYDROOROTIC AND ACID DEHYDROGENASE INHIBITOR | NAI INC. | 2016-10-13 | — | — | US | disclosed |
| US-9440913-B2 | Dihydroxybenzene derivatives and antiprotozoal agent comprising same as active ingredient | NAI INC. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-9440913-B2 | Dihydroxybenzene derivatives and antiprotozoal agent comprising same as active ingredient | NAI INC. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20150166498-A1 | DIHYDROOROTIC ACID DEHYDROGENASE INHIBITOR | NAI INC. (JP) | 2015-06-18 | — | — | US | disclosed |
| US-20150166498-A1 | DIHYDROOROTIC ACID DEHYDROGENASE INHIBITOR | NAI INC. (JP) | 2015-06-18 | — | — | US | disclosed |
| EP-2857010-A1 | DIHYDROOROTIC ACID DEHYDROGENASE INHIBITOR | NAI Inc. (JP) | 2015-04-08 | — | — | EP | disclosed |
| US-20130296422-A1 | Novel Dihydroxybenzene Derivatives and Antiprotozoal Agent Comprising Same as Active Ingredient | ARIGEN PHARMACEUTICALS, INC. (JP) | 2013-11-07 | — | — | US | disclosed |
| US-20130296422-A1 | Novel Dihydroxybenzene Derivatives and Antiprotozoal Agent Comprising Same as Active Ingredient | ARIGEN PHARMACEUTICALS, INC. (JP) | 2013-11-07 | — | — | US | disclosed |
| EP-2636663-A1 | NOVEL DIHYDROXYBENZENE DERIVATIVES AND ANTIPROTOZOAL AGENT COMPRISING SAME AS ACTIVE INGREDIENT | aRigen Pharmaceuticals, Inc. (JP) | 2013-09-11 | — | — | EP | disclosed |
| WO-2012060387-A1 | NOVEL DIHYDROXYBENZENE DERIVATIVES AND ANTIPROTOZOAL AGENT COMPRISING SAME AS ACTIVE INGREDIENT | アリジェン製薬株式会社 (JP) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166498-A1 | DIHYDROOROTIC ACID DEHYDROGENASE INHIBITOR | DHODH, DPYD, DLD | ALDH1A1 93/4885LMNA 4866/4885EPHX2 2152/4885 |
| US-20130296422-A1 | Novel Dihydroxybenzene Derivatives and Antiprotozoal Agent Comprising Same as Active Ingredient | CBR3, CBR1, DHX35 | ALDH1A1 1072/4885LMNA 3363/4885EPHX2 708/4885 |
| US-20160296494-A1 | DIHYDROOROTIC AND ACID DEHYDROGENASE INHIBITOR | DHODH, DPYD, DLD | ALDH1A1 75/4885LMNA 4867/4885EPHX2 1773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.